Loading…
← CockpitCompetitor Analysis › 3759.HK Pharmaron Beijing Co., Ltd. Class HOpen in the cockpit ↗

Pharmaron Beijing Co., Ltd. Class H3759.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.

≈ A Chinese CRO/CDMO akin to a smaller Charles River LaboratoriesMomentum leader 89
Mkt cap
$9.65B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$22.8M
20-day average traded
Fwd P/E
20.8×
forward earnings
ROIC−WACC
-1.6 pp
WACC 14.1%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · HKDHK$26.88
1D-3.5%
1W-9.4%
1M-0.9%
3M-14.5%
6M+48.4%
YTD+37.2%
1Y+11.0%
ATR %6.6%
52w lowhigh22.9% off high

What Pharmaron Beijing does

Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.

Same company as the Shenzhen-listed A shares. Is paid for services rather than for drugs: chemists billed by headcount for discovery work, and per project or batch for development and manufacturing. US and European clients provide most of the revenue.

In one line: A Chinese CRO/CDMO akin to a smaller Charles River Laboratories.

Products and services

  • Drug discovery services
  • Preclinical/clinical development services
  • CDMO manufacturing

Customers

  • Global biopharma and biotech companies outsourcing

Where it sits in the supply chain

  • Healthcare
  • Biopharma CRO/CDMO
  • Drug discovery, development…

What could go right

  • Global biopharma R&D outsourcing growth
  • Overseas capacity expansion

What could go wrong

  • US biosecurity/outsourcing policy risk
  • Biopharma R&D spending cyclicality

Moat: narrow (process know-how, customer qualification, scale). Deep scientific know-how and long-standing outsourcing relationships across the drug-development chain.

Headquarters: Beijing, China · Founded: 1996 · Employees: 25,088

Named competitors

Pharmaron Beijing at a glance

Size Pharmaron Beijing (3759.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $9.65B, the 164th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$26.88 on 18 Nov 2026.

Performance Over six months the shares gained 48.4%, against +9.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 24.2% over the last twelve months (peer median +10.4%); the operating margin is 14.4% (peer median 17.6%).

Valuation It trades at 20.8× forward earnings against a peer median of 25.2× (8th cheapest of 16).

Capital Return on invested capital runs 1.6 points below its cost of capital (14.1% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 20263759.HK 147Peer median 112
Six months, rebased to 100: Pharmaron Beijing against the median of its 20 peers (local-currency closes).

Pharmaron Beijing financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$18.2BHK$15.3BHK$13.3BHK$12.7BHK$11.9B
Revenue growth—+15%+5%+7%—
Gross profitHK$7.07BHK$4.98BHK$4.50BHK$4.27BHK$4.14B
EBITDAn/aHK$3.60BHK$3.10BHK$2.94BHK$2.83B
Net incomeHK$2.01BHK$1.80BHK$1.94BHK$1.77BHK$1.60B
Free cash flow-HK$236MHK$674MHK$633M-HK$68.8M-HK$867M
Capital expenditureHK$3.42BHK$2.89BHK$2.21BHK$3.17BHK$3.43B
Total debtHK$8.74BHK$7.84BHK$6.36BHK$10.7BHK$6.89B

Quarterly statements and history in the cockpit →

Pharmaron Beijing competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%SYRETGTXMDGLHLUN-APRAXRGEN4151PTGX2607RYTMMANKIND600436GLENMARKALK-BALKSREC21961177AMRXGRF3759.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Pharmaron Beijing is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×TGTXMDGLRGEN4151PTGX26076004363759.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pharmaron Beijing is the large dot.

Pharmaron Beijing competitors and peer comparison

Head to head with its named competitors (3759.HK vs 2359.HK vs CRL vs 6821.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Pharmaron Beijing 3759.HK$9.65B+48%+24%14%20.8×n/a
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Asymchem Laboratories (Tianjin) 6821.HK$7.10B+17%+24%17%24.4×n/a
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%

How Pharmaron Beijing compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pharmaron Beijing against its 20 peers (data as of 18 Nov 2026)
Measure3759.HKPeer medianRank in peer set
1-month return-0.9%+7.9%6th lowest of 21
6-month return+48.4%+9.6%5th highest of 21
Distance from 52-week high-22.9%-10.8%5th lowest of 21
Revenue growth (TTM)+24.2%+10.4%5th highest of 20
Operating margin14.4%17.6%7th lowest of 19
Forward P/E20.8×25.2×8th cheapest of 16
ROIC minus cost of capital-1.6 pp+1.4 pp7th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%20.8×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%

Questions

Who are Pharmaron Beijing's main competitors?
Named competitors: WuXi AppTec (2359.HK), Charles River Laboratories (CRL), Asymchem Laboratories (6821.HK), Lonza (LONN.SW). The cockpit's measured peer set (industry) also includes Spyre Therapeutics (SYRE), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), H. Lundbeck A/S (HLUN-A.CO), Praxis Precision Medicines (PRAX), Repligen (RGEN).
Is Pharmaron Beijing expensive compared with its peers?
On forward p/e it trades at 20.8× against a peer median of 25.2×, 8th cheapest of 16 in its peer set.
How has Pharmaron Beijing stock performed?
Over six months to 18 Nov 2026 the shares returned +48.4% against +9.6% for the median peer; over one year +11.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.